00:0050 years ago Zucca Pharmaceutical started its research and development activities in the CNS area,
00:10that is, psychiatry and neurology.
00:12Fortunately, they found important solutions that became market leaders in the psychiatric area,
00:19especially in psychosis.
00:21After that, in recent years, it has also developed all the research and development in the nephrological area.
00:27More recently, a product with a nephritic lupus indication was launched
00:32and now, in Italy, we are introducing a new treatment for acute myeloid leukemia.
00:37But this is the present, there is much to be expected for the future.
00:40We are entering new therapeutic areas, but all of them in rare diseases,
00:44especially in the accumulation nephropathy of immunoglobulin A,
00:48hereditary angioedema, phenylketonuria,
00:51which was announced last week in the SLA with FUHR genetic mutation.
Comments